Biotechnology AVX,ACR,AVP.......

[Joshuatree]

BOT( spekky DYOR)

Botanix Pharmaceuticals was recently covered by a range of analysts and research notes which highlighted the company’s key investment drivers as well as the unique proposition the company offers to investors.

Banyan Tree Investment Group produced an in-depth research note which detailed how the company’s leading acne product, BTX1503, could unlock significant value and that Botanix
“remains attractively priced in absolute terms relative to its ASX-listed cannabis and pharmaceuticals peers”. Click here to read the full report.

Botanix was also featured in the April edition of The Passionate Investor and Under The Radar. Both reported on the company’s activities and the use of synthetic cannabidiol as the novel drug active, which is preferred by regulators for its pharmaceutical grade quality and purity. Click here for the issue of The Passionate Investor (please refer to page 21) and here for the Under the Radar Report.

Lastly, earlier in March, Argonaut also initiated coverage of Botanix which highlighted that BTX1503 has “the potential to be a ‘game-changing’ treatment for moderate to severe acne”. Click here for the full report.

Botanix also recently conducted a video interview with its Executive Director Matt Callahan where he discussed the company’s commencement of Phase 1a study for BTX1503 and upcoming milestones. Click here to view the video.

For more information about Botanix, please subscribe to the company’s investor updates by emailing achan[@]buchanwe.com.au.

Note: Botanix does not endorse, confirm, or express a view as to the accuracy of, the forecasts or other statements contained in the materials cited above. Botanix should not be taken to make any representation about its future performance by citing those materials